Gan & Lee Pharmaceuticals. (603087.SS)
| Previous Close | 72.18 |
| Open | 71.74 |
| Bid | 69.92 x N/A |
| Ask | 69.93 x N/A |
| Day's Range | 69.88 - 72.11 |
| 52 Week Range | 65.00 - 181.28 |
| Volume | |
| Avg. Volume | 4,263,180 |
| Market Cap | 39.263B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | 27.28 |
| EPS (TTM) | 2.56 |
| Earnings Date | Oct. 28, 2021 - Oct. 29, 2021 |
| Forward Dividend & Yield | 0.40 (0.56%) |
| Ex-Dividend Date | May 21, 2021 |
| 1y Target Est | N/A |
- CNW Group
Gan & Lee Pharmaceuticals Concludes Phase 3 Studies of Gan & Lee Insulin Glargine (GL-GLA)
Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee) (Shanghai: 603087.SH), is pleased to announce the completion of two randomized, multicenter, phase 3 studies that compare proposed biosimilar Gan & Lee insulin glargine (GL-GLA) to a reference biologic. The two studies were conducted separately in subjects with type 1 (n=576) and type 2 diabetes mellitus (n=567).
- CNW Group
Gan & Lee Pharmaceuticals to present data at the 57th Annual European Association for the Study of Diabetes Meeting
Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087.SH), is excited to present positive data from five abstracts which will be featured as short oral discussions at the 57th Annual European Association for the Study of Diabetes (EASD) Meeting. The meeting will be held virtually from September 27th – October 1st, 2021.
- CNW Group
New Data on Phase 1 Proposed Biosimilar Gan & Lee Insulins Aspart (GL-ASP), Lispro (GL-LIS), and Glargine (GL-GLA) Presented at the American Diabetes Association's 81st Scientific Sessions
Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087.SH), announced positive Phase 1 clinical trial results at the 81st Scientific Sessions of the American Diabetes Association (ADA), June 25th – 29th. The new data pertained to three proposed biosimilar Gan & Lee insulin analogs, insulin aspart (GL-ASP), insulin lispro (GL-LIS), and insulin glargine (GL-GLA), and were presented by the primary investigators from Profil, (Germany).
